General Information of Drug (ID: DMADNY3)

Drug Name
SHR-1314 Drug Info
Indication
Disease Entry ICD 11 Status REF
Plaque psoriasis EA90.0 Phase 1/2 [1]
Cross-matching ID
TTD Drug ID
DMADNY3

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug(s) Targeting Interleukin-17 (IL17)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Brodalumab DMASDQ6 Plaque psoriasis EA90.0 Approved [2]
Bimekizumab DMR9TF1 Plaque psoriasis EA90.0 Approved [1]
Ixekizumab DMXW92T Plaque psoriasis EA90.0 Approved [3]
CNTO-6785 DM6RQXB Rheumatoid arthritis FA20 Phase 2 [4]
ABT-122 DM23UQ9 Psoriatic arthritis FA21 Phase 2 [5]
CJM112 DMTSVJM Acne vulgaris ED80 Phase 2 [6]
COVA322 DM824EG Psoriasis vulgaris EA90 Phase 1/2a [7]
ABBV-257 DMCZI8L Rheumatoid arthritis FA20 Phase 1 [8]
ALX-0761 DMJ8ACF Psoriasis vulgaris EA90 Phase 1 [7]
SCH-900117 DM7A6R5 Rheumatoid arthritis FA20 Phase 1 [9]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Interleukin-17 (IL17) TTG0MT6 IL17_HUMAN Inhibitor [1]

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
3 Brodalumab and ixekizumab, anti-interleukin-17-receptor antibodies for psoriasis: a critical appraisal. Br J Dermatol. 2012 Oct;167(4):710-3; discussion 714-5.
4 Targeting the IL-17-T(H)17 pathway. Nat Rev Drug Discov. 2015 Jan;14(1):11-2.
5 DOI: 10.1136/annrheumdis-2015-eular.4042
6 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
7 Bispecific antibodies rise again. Nat Rev Drug Discov. 2014 Nov;13(11):799-801.
8 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
9 Targeting IL-17 and TH17 cells in chronic inflammation. Nat Rev Drug Discov. 2012 Oct;11(10):763-76.